REYKJAVIK, Iceland — 13 Nov, 2024 — Akthelia Pharmaceuticals is featured in today’s edition of the leading Icelandic business newspaper Viðskiptablaðið.
The article highlights the opportunity to advance our highly promising oral NCE therapeutic asset Gastrimod™️ (AKT-011) that we are exploring both for oncology and inflammatory bowel disorders, as it targets mucositis/mucosal barrier injury. MBI has emerged as the common pathology underlying infection and sepsis risk that presents as febrile neutropenia, the leading dose-limiting complication and cause of treatment-related mortality in cancer treatment, HSCT and GVHD.
Full PR available here